Whereas clinical trials evaluating the efficacy of PLK1 inhibitors in the treatment of a variety of cancers did not find inclusion of these inhibitors in therapeutic regimens to be broadly efficacious, there were subsets of patients who demonstrated clinical benefit from PLK1 inhibition (31, 35–38). The gene discussed is PLK1; the disease is cancer.